Hypertension最新文献

{"title":"Subclinical Postpartum Renal Structure After Hypertensive Pregnancy Disorders.","authors":"Hannah R Cutler, Jamie Kitt, Prenali D Sattwika, Lucy E M Finnigan, Ana Estevez-Fernandez, Yvonne Kenworthy, Katie Suriano, Annabelle Frost, Samuel Krasner, Casey Johnson, Annabelle McCourt, Rebecca Mills, Katherine Tucker, Alexandra Cairns, Cristian Roman, Christina Aye, Lucy Mackillop, Basky Thilaganathan, Lucy C Chappell, Betty Raman, Adam J Lewandowski, Winok Lapidaire, Paul Leeson","doi":"10.1161/HYPERTENSIONAHA.125.25130","DOIUrl":"https://doi.org/10.1161/HYPERTENSIONAHA.125.25130","url":null,"abstract":"<p><strong>Background: </strong>Hypertensive pregnancies are associated with increased risks of renal failure in pregnancy and later life. However, traditional markers of renal function normalize postpartum, making identification of those at future disease risk difficult. We studied whether the type and severity of hypertensive pregnancy associated with postpartum renal structure.</p><p><strong>Methods: </strong>One hundred twenty-five women from interventional trials (61 preeclamptic, 33 gestational hypertension, and 31 normotensive pregnancy), aged ≥18 years, were imaged using magnetic resonance imaging 6 to 12 months postpartum. Anthropometric, demographic, blood pressure, and blood sample data were collected during pregnancy and postpartum. Kidney volume indexed to body surface area and corticomedullary differentiation were compared between groups using a 1-way ANCOVA, whereas associations with other outcomes were assessed using correlation tests.</p><p><strong>Results: </strong>Postpartum total kidney volume indexed to body surface area was smaller in women who had preeclampsia compared with those who had gestational hypertension or a normotensive pregnancy (<i>P</i>=0.049). Total kidney volume postpartum correlated with estimated glomerular filtration rate at delivery (<i>P</i><0.001). However, smaller volumes were not explained by reduced corticomedullary differentiation, which only differed in women with gestational hypertension compared with preeclamptic (<i>P</i>=0.02) and normotensive women (<i>P</i>=0.007). There were no associations between renal measures and blood pressure during or after pregnancy.</p><p><strong>Conclusions: </strong>At 6 to 12 months postpartum, preeclamptic women have smaller kidney volumes than women with gestational hypertension or normotensive pregnancies. These smaller volumes relate to lower renal function at delivery but not corticomedullary differentiation, which only differed in women with gestational hypertension.</p><p><strong>Registration: </strong>URL: https://www.clinicaltrials.gov; Unique identifiers: NCT04273854 and NCT05434195.</p>","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144952121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Debate on the 2025 Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: New Blood Pressure Targets, Lower Is Better-And Possible.","authors":"Lucas Lauder, Kazem Rahimi, Michael Böhm, Felix Mahfoud","doi":"10.1161/HYPERTENSIONAHA.125.25466","DOIUrl":"https://doi.org/10.1161/HYPERTENSIONAHA.125.25466","url":null,"abstract":"<p><p>The American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines has now released the long-awaited 2025 American Heart Association/American College of Cardiology/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Since the previous version, which had been in place for 8 years, meta-analyses and several treat-to-target trials investigating lower versus standard blood pressure targets have been published. Based on these, the 2025 American College of Cardiology/American Heart Association guideline recommends in adults with confirmed hypertension, an office blood pressure goal of <130/80 mm Hg, with encouragement to further reduce systolic blood pressure to <120 mm Hg. Here, we set out why we support these lower blood pressure targets and outline strategies to achieve them.</p>","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144952114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of Risk Assessment to Guide Decision-Making for Blood Pressure Management in the Primary Prevention of Cardiovascular Disease: A Scientific Statement From the American Heart Association and American College of Cardiology.","authors":"Sadiya S Khan, Marwah Abdalla, Natalie A Bello, Ciantel A Blyler, Jocelyn Carter, Yvonne Commodore-Mensah, Keith C Ferdinand, Heather M Johnson, Daniel Jones, Amit Khera, Paul Muntner, Stacey Schott, Daichi Shimbo, Sidney C Smith, Sandra J Taler, Eugene Yang, Donald M Lloyd-Jones","doi":"10.1161/HYP.0000000000000248","DOIUrl":"https://doi.org/10.1161/HYP.0000000000000248","url":null,"abstract":"<p><p>Risk assessment plays a central role in the primary prevention of cardiovascular disease. The 2017 High Blood Pressure Clinical Practice Guideline incorporated quantitative risk assessment for the first time to guide the initiation of antihypertensive drug therapy and recommended calculation of 10-year risk of atherosclerotic cardiovascular disease with the Pooled Cohort Equations. Although the 2025 High Blood Pressure Guideline reaffirmed this overarching paradigm for risk-based initiation of antihypertensive drug therapy, it updated the recommended risk model to the Predicting Risk of Cardiovascular Disease Events equations, which estimate 10-year risk of total cardiovascular disease (including atherosclerotic cardiovascular disease and heart failure), and defined a new risk threshold for initiation of antihypertensive therapy in patients with stage 1 hypertension. This American Heart Association/American College of Cardiology scientific statement summarizes the rationale to recommend the use of the Predicting Risk of Cardiovascular Disease Events equations, the evidence base for the new threshold of 10-year risk of cardiovascular disease of ≥7.5%, and the population-level implications of these revised recommendations. This scientific statement also offers practical advice for implementing risk assessment as the first step in the comprehensive approach to hypertension management with shared decision-making between patients and clinicians. Remaining gaps in awareness and treatment of hypertension underscore the need for innovative strategies to improve implementation of and adherence to risk-based guideline recommendations, including automation of risk assessment in electronic health records, decision-support aids, and refinement of risk assessment, to equitably improve the initiation of antihypertensive drug therapy, blood pressure control, and outcomes.</p>","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144952150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Debate on the 2025 Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Emphasis on Defense Against the BP Threshold and Why We May Not Get There Easily.","authors":"Raymond R Townsend","doi":"10.1161/HYPERTENSIONAHA.125.25468","DOIUrl":"https://doi.org/10.1161/HYPERTENSIONAHA.125.25468","url":null,"abstract":"<p><p>Elevated blood pressure (BP) is the most important noncommunicable disorder worldwide. Finding and effectively managing elevated BP is the single greatest public health benefit we can accomplish, as it will reduce premature death and enable patients to live longer free of the disabilities that target organ damage inflicts on the brain, heart, kidneys, and legs. Hypertension guidelines are an invaluable source of information on how to detect elevated BP, how to evaluate people for situations where hypertension is a symptom of other disorders, and how to apply the various treatments that lower BP effectively in patients. Determining the point at which treating high BP is more likely to result in benefit than harm is a marriage of science and art. There is no right answer to what clearly constitutes hypertension when using a systolic or diastolic BP to define it. The science shows the mathematics behind the reduction of BP and the number of lives saved and target organs preserved. The art comes into play when a decision is made that, when a systolic or diastolic BP exceeds a certain level, it becomes reasonable to intervene at that point with treatment. Caregivers play an important role in monitoring and educating patients with hypertension-especially in the detection of unintended effects of treatment, such as excessive BP lowering, symptomatic hypotension, and impacts on laboratory tests and well-being. Nonadherence to prescribed therapies is a barrier to effectively managing chronic disorders like hypertension. Having a solid foundation in the science behind the guidelines and recognizing that the application of guidelines requires some clinical judgment gleaned from balancing the risks and benefits of treatment in each individual patient, is the basis for healthy exchanges of ideas, like this pro and con series which discusses the science and furthers the art. This review has taken the con side of several issues in the latest American College of Cardiology/American Heart Association 2025 Hypertension Guidelines.</p>","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144952102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing Risk-Based Approaches in Blood Pressure Management: Reflections on the 2025 AHA/ACC Statement.","authors":"Kazem Rahimi, Milad Nazarzadeh, Anthony Rodgers","doi":"10.1161/HYPERTENSIONAHA.125.25564","DOIUrl":"10.1161/HYPERTENSIONAHA.125.25564","url":null,"abstract":"","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144952159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular Effects of Sucrose in Experimental Animals and Humans.","authors":"Yuki Nakayama, Katherine J Elliott, Satoru Eguchi","doi":"10.1161/HYPERTENSIONAHA.125.25720","DOIUrl":"https://doi.org/10.1161/HYPERTENSIONAHA.125.25720","url":null,"abstract":"<p><p>Sucrose, a disaccharide composed of glucose and fructose, is one of the most widely consumed dietary sugars. The recent global rise in sugar intake is a growing concern regarding its potential contribution to the development of metabolic and cardiovascular disorders. While the metabolic effects of glucose and fructose have been extensively studied individually, the impact of sucrose on cardiovascular health remains an evolving area of research. In rats with a high-sucrose diet, hallmarks of metabolic syndrome were observed including weight gain, insulin resistance, ≈15-mm Hg elevation in blood pressure, and systemic inflammation. It also caused disruptions in gut microbiota. Recently, we reported that high-sucrose ingestion via drinking water induces hypertension and cardiovascular complications associated with hyperinsulinemia in mice. In humans, excessive sucrose intake is associated with elevated plasma glucose, insulin, and lipid levels, particularly in individuals with obesity. Although long-term epidemiological data are limited, a recent study demonstrated that sucrose intake increased the risk for hypertension in women. These findings highlight the need to reassess the relationship between sucrose consumption and cardiovascular disease in humans. This review discusses current evidence from both animal and human studies covering molecular mechanisms and pathophysiological outcomes to explore how sucrose influences cardiovascular and metabolic health. As sucrose remains a major component of global diets, particularly in industrialized nations, further longitudinal and mechanistic studies are needed to clarify its long-term health consequences. Reducing excess sucrose intake may represent a prudent public health strategy, especially for individuals at increased risk for cardiovascular diseases including hypertension.</p>","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144952141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating Blood Pressure Response Patterns to Exercise Stress Testing.","authors":"Aishwarya Nene, Dana Lee, Olayinka Agboola, Jeph Herrin, Oyere K Onuma, Attila Feher, Edward J Miller, Yuan Lu, Judith Meadows, Erica S Spatz","doi":"10.1161/HYPERTENSIONAHA.124.23717","DOIUrl":"https://doi.org/10.1161/HYPERTENSIONAHA.124.23717","url":null,"abstract":"<p><strong>Background: </strong>A hypertensive response to exercise unmasks hypertension and is associated with future cardiovascular events. Yet, there is heterogeneity in blood pressure response patterns to exercise by age and sex, and some high-risk trajectories may go undetected if only focusing on peak blood pressure.</p><p><strong>Methods: </strong>We analyzed blood pressure data from 13 945 patients who underwent a Bruce protocol exercise tolerance test between 2016 and 2020, including the rate of change across stages. We used latent class analysis to identify distinct blood pressure trajectories and assessed their association with individual and composite outcomes of myocardial infarction, stroke, heart failure, revascularization, and death.</p><p><strong>Results: </strong>Women had lower mean systolic and diastolic blood pressure at rest (128 mm Hg versus 132 mm Hg; 78 mm Hg versus 80 mm Hg) and through stages 1 to 3 of the Bruce protocol (stage 1: 140 mm Hg versus 144 mm Hg; 78 mm Hg versus 80 mm Hg; stage 2: 153 mm Hg versus 157 mm Hg; 79 mm Hg versus 81 mm Hg; stage 3: 159 mm Hg versus 167 mm Hg; 80 mm Hg versus 82 mm Hg). Systolic blood pressure increased more slowly in women. Three distinct systolic blood pressure trajectories emerged, with steeper trajectories associated with older populations and men. Systolic Classes II and III, characterized as an elevated baseline and a gradual rise (Class II) and a steep rise (Class III) with exercise, were associated with cardiovascular outcomes. Yet, only 1.4% and 34% of patients in Class II and III, respectively, met traditional criteria for hypertensive response to exercise, suggesting missed opportunities for prevention and treatment.</p><p><strong>Conclusions: </strong>Blood pressure response to exercise varies by sex; models incorporating trajectories of blood pressure could more fully capture individuals at higher risk for future cardiovascular events.</p>","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144952092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"c-Fos Mediates Preeclampsia Through p-AMPK/Detyrosinated Tubulin Pathway.","authors":"Yihong Huang, Shanshan Zhao, Chumei Zeng, Shaole Shi, Zhuyu Li, Lixia Shen, Huizhen Geng, Zilian Wang, Dongyu Wang","doi":"10.1161/HYPERTENSIONAHA.124.24416","DOIUrl":"https://doi.org/10.1161/HYPERTENSIONAHA.124.24416","url":null,"abstract":"<p><strong>Background: </strong>Preeclampsia is a systemic disorder unique to pregnancy that is associated with trophoblast dysfunction. Although the c-Fos (FBJ osteosarcoma oncogene) is essential for placental development, its mechanistic role in preeclampsia remains unclear.</p><p><strong>Methods: </strong>We identified c-Fos as a hub gene through an analysis of cell-free RNA from maternal plasma and single-cell RNA sequencing of preeclamptic placentas. We assessed c-Fos expression in the placenta and plasma and examined its correlation with lipids. Functional changes upon the viral modulation of c-Fos in trophoblast cells were evaluated. Untargeted lipidomics and RNA sequencing were conducted to uncover the downstream mechanisms, and the findings were validated in trophoblast cells and a preeclampsia-like murine model.</p><p><strong>Results: </strong>c-Fos expression was decreased in maternal peripheral plasma from early to mid-pregnancy and in the placenta of preeclampsia patients. Furthermore, c-Fos expression levels were negatively correlated with neutral lipid accumulation. c-Fos deficiency impaired trophoblast invasion, proliferation, and syncytialization while promoting apoptosis. Reduced c-Fos expression also led to lipid droplet aggregation and mitochondrial dysfunction. Mechanistically, c-Fos silencing inhibited the p-AMPK (phosphorylated AMP-activated protein kinase)/detyrosinated tubulin pathway, disrupting lipid droplet trafficking and metabolism and promoting lipid droplet accumulation and an altered lipid profile. c-Fos deficiency induced a preeclampsia-like phenotype in mice, whereas c-Fos overexpression partially alleviated preeclampsia symptoms.</p><p><strong>Conclusions: </strong>c-Fos downregulation inhibits the p-AMPK/detyrosinated tubulin pathway, driving lipid droplet accumulation and consequent trophoblast dysfunction, revealing c-Fos as a potential therapeutic target for preeclampsia.</p>","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144952085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overcoming Barriers to Developing and Implementing Novel Therapies for Hypertension.","authors":"Konstantin A Krychtiuk, Renato D Lopes, Victoria A Cargill, Roland Chen, Martin R Cowie, William C Cushman, Mitchell S V Elkind, Shilpi Epstein, Pushkal P Garg, Bernard J Gersh, Michail Giakoumis, Jennifer B Green, Weinong Guo, Ajay J Kirtane, Marty Lefkowitz, Anastasia Lesogor, George A Mensah, Michelle L O'Donoghue, E Magnus Ohman, Neha J Pagidipati, David Reboussin, Lothar Roessig, Veronique L Roger, Eduardo Sanchez, Norman Stockbridge, Rhian M Touyz, Harriette G C Van Spall, Michael A Weber, Seamus P Whelton, Adrian F Hernandez, Clyde W Yancy, Christopher B Granger","doi":"10.1161/HYPERTENSIONAHA.125.24992","DOIUrl":"https://doi.org/10.1161/HYPERTENSIONAHA.125.24992","url":null,"abstract":"<p><p>Hypertension is the single most important modifiable risk factor for preventable disability and death worldwide and disproportionately affects socially disadvantaged populations. We face a paradox-blood pressure control is low and recent trends suggest it is even declining, despite the availability of inexpensive and effective therapies. A variety of barriers on the system, patient, and healthcare provider side hinder effective drug-based risk factor management. Clinical inertia represents a major barrier on the clinician side, as well as workload and limited education. Common barriers on the patient side include limited English proficiency, low health literacy, and nonadherence with misaligned incentives, limited resources, lack of structured clinical pathways, and reimbursement issues. New innovations in the field of RNA-targeted therapies and device-based interventions could prevent and potentially even cure diseases previously designated as chronic health conditions, such as hypertension. Such novel therapies could potentially overcome several major barriers to effective treatment, including nonadherence. Drug development of novel, long-acting treatments requires consideration of specific clinical trial design aspects, including safety collection, benefit: risk assessment, the development and assessment of novel, qualitative surrogate end points, such as time-in-therapeutic range, the use of representative trial settings as well as the definition of standard of care in placebo-controlled trials, which should be of reasonably high-quality allowing for credible evaluation of effectiveness. Here, we provide an overview on barriers to effective treatment and a framework for trials assessing novel treatments for cardiovascular disease risk factors, including early and broad implementation programs.</p>","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144952099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanisms of Elevated Cutaneous Vascular Tone in College-Aged Black Individuals.","authors":"John D Akins, Rauchelle E Richey, Zachary T Martin, Paul J Fadel, R Matthew Brothers","doi":"10.1161/HYPERTENSIONAHA.125.24701","DOIUrl":"10.1161/HYPERTENSIONAHA.125.24701","url":null,"abstract":"<p><strong>Background: </strong>Hypertension prevalence is greatest in the US non-Hispanic Black population, possibly through reduced vascular function. Although heightened cutaneous vascular tone and vasoconstrictor responsiveness have been reported in Black individuals, the underlying physiological mechanisms remain unknown.</p><p><strong>Methods: </strong>Thirteen Black (6 women, 22±2 years) and 10 non-Hispanic White (4 women, 25±4 years) participants underwent intradermal perfusion of norepinephrine alone (10^-⁸ to 10^-² M; control) or coinfused with ascorbic acid (general antioxidant), L-NAME (<i>N</i>^ω-nitro- L-arginine methyl ester; a nitric oxide synthase inhibitor), or combined ascorbic acid and l-NAME. Cutaneous vascular conductance was used to estimate vascular tone.</p><p><strong>Results: </strong>Non-Hispanic Black participants had lower absolute conductance at the control (<i>P</i>=0.012), but not ascorbic acid or l-NAME sites (both <i>P</i>>0.123). Black participants also had lower absolute baseline conductance at all sites (0.26±0.13 versus 0.37±0.14 flux/mm Hg) and across the norepinephrine perfusions (≈51% lower; both <i>P</i><0.05). At baseline and across norepinephrine perfusions, ascorbic acid increased absolute conductance compared with control in both groups (Black: +94%; White: +39%), while l-NAME reduced absolute conductance in the White participants only (-43%; all <i>P</i><0.05). Across all doses, control relative conductance was not different between the groups (<i>P</i>>0.05), though the ascorbic acid and combined sites in the Black participants and all sites in the White participants produced greater relative conductance than control (all <i>P</i><0.05).</p><p><strong>Conclusions: </strong>These data suggest greater tonic, but not norepinephrine-induced, cutaneous vasoconstriction in Black individuals, which appears to be mediated by greater oxidative stress contributing to reduced nitric oxide bioavailability.</p>","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144882803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}